Abstract
Cardiovascular disease is the leading cause of morbidity and mortality in the Western world. However, it appears that currently available risk assessment tools often underestimate risk, especially for patients in the intermediate-risk category. Considering the socioeconomic cost, it is imperative to correctly identify patients in the intermediate-risk category who would benefit from more aggressive treatment. A plethora of experimental and observational studies provide support that lipoprotein associated phospholipase A2 (Lp- PLA2) and secretory phospholipases A2 (sPLA2) as well as high sensitivity C-reactive protein (hsCRP) are useful biomarkers of cardiovascular risk. Particularly, Lp-PLA2) has also been addressed as pharmacological target and we are eagerly awaiting the results of ongoing phase III clinical trials. In this review we discuss the current literature regarding the pros and cons of these biomarkers.
Keywords: Atherosclerosis, biomarkers, cardiovascular disease, hsCRP, inflammation, Lp-PLA2, PAF-acetylhydrolase, sPLA2.
Current Pharmaceutical Design
Title:Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Volume: 19 Issue: 21
Author(s): Elisavet Moutzouri, Vasilis Tsimihodimos and Alexandros D. Tselepis
Affiliation:
Keywords: Atherosclerosis, biomarkers, cardiovascular disease, hsCRP, inflammation, Lp-PLA2, PAF-acetylhydrolase, sPLA2.
Abstract: Cardiovascular disease is the leading cause of morbidity and mortality in the Western world. However, it appears that currently available risk assessment tools often underestimate risk, especially for patients in the intermediate-risk category. Considering the socioeconomic cost, it is imperative to correctly identify patients in the intermediate-risk category who would benefit from more aggressive treatment. A plethora of experimental and observational studies provide support that lipoprotein associated phospholipase A2 (Lp- PLA2) and secretory phospholipases A2 (sPLA2) as well as high sensitivity C-reactive protein (hsCRP) are useful biomarkers of cardiovascular risk. Particularly, Lp-PLA2) has also been addressed as pharmacological target and we are eagerly awaiting the results of ongoing phase III clinical trials. In this review we discuss the current literature regarding the pros and cons of these biomarkers.
Export Options
About this article
Cite this article as:
Moutzouri Elisavet, Tsimihodimos Vasilis and D. Tselepis Alexandros, Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives, Current Pharmaceutical Design 2013; 19 (21) . https://dx.doi.org/10.2174/13816128113199990307
DOI https://dx.doi.org/10.2174/13816128113199990307 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perivascular Inflammation and Hypertensive Cardiovascular Remodeling
Current Hypertension Reviews Gene Therapy for Osteoinduction
Current Gene Therapy Fabrication and Physicochemical and Medicinal Characterization of Nano Traditional Chinese Medicine
Recent Patents on Engineering Melatonin, a Potential Therapeutic Agent for Smooth Muscle-Related Pathological Conditions and Aging
Current Medicinal Chemistry Redox State in Atrial Fibrillation Pathogenesis and Relevant Therapeutic Approaches
Current Medicinal Chemistry Impact of Mitochondrial Toxicity of HIV-1 Antiretroviral Drugs on Lipodystrophy and Metabolic Dysregulation
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Traditional Medicine Endocannabinoid Receptor Antagonists and Other Emerging Pharmacological Strategies for Weight Reduction
Current Drug Targets - Cardiovascular & Hematological Disorders The Fetal Cardiac Function
Current Cardiology Reviews The Therapeutic Potential of Hepatocyte Growth Factor for Myocardial Infarction and Heart Failure
Current Pharmaceutical Design Testosterone Replacement Therapy in Older Male Subjective Memory Complainers: Double-Blind Randomized Crossover Placebo-Controlled Clinical Trial of Physiological Assessment and Safety
CNS & Neurological Disorders - Drug Targets The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Current Pharmaceutical Design A Case of 2:1 Atrio-Ventricular Block- Unraveled by Exercise Testing
New Emirates Medical Journal Risk Factors of Alzheimers Disease Among Iranian Population
Current Alzheimer Research Targeting Adenosine Signaling to Treatment of Diabetic Nephropathy
Current Drug Targets Patenting Penicillium Strains
Recent Patents on Biotechnology Prevention of Bioprosthetic Heart Valve Calcification: Strategies and Outcomes
Current Medicinal Chemistry Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design Editorial [Hot Topic:Metabolic Therapy: An Important Therapeutic Option for the Treatment of Cardiovascular Diseases (Executive Editors: G.M.C. Rosano and G. Barbaro)]
Current Pharmaceutical Design Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]
Current Vascular Pharmacology